草酸艾司西酞普兰联合经颅磁刺激对青壮年卒中后抑郁的治疗研究  

Escitalopram oxalate combined with transcranial magnetic stimulation in the treatment of poststroke depression in young adults

作　　者：高天初 刘喜艳[2] 齐伟静[1] 卢军栋[1] 鲁娜[1] Gao Tianchu;Liu Xiyan;Qi Weijing;Lu Jundong;Lu Na(Department of Neurology,the Baoding No.1 Central Hospital,Hebei 071000,China)

机构地区：[1]保定市第一中心医院,河北071000 [2]河北省第六人民医院

出　　处：《脑与神经疾病杂志》2023年第12期776-779,共4页Journal of Brain and Nervous Diseases

基　　金：保定市科技计划项目(2141ZF066)。

摘　　要：目的探讨经颅磁刺激(rTMS)联合草酸艾司西酞普兰治疗青壮年卒中后抑郁(PSD)的治疗效果。方法选取2021年6月至2023年7月就诊于保定市第一中心医院与河北省第六人民医院的的青壮年PSD患者共106例,随机分为草酸艾司西酞普兰治疗组(38例)、草酸艾司西酞普兰联合高频rTMS治疗组(32例)及草酸艾司西酞普兰联合低频rTMS治疗组(36例),经过4 w治疗后采用汉密尔顿抑郁量表17(HAMD-17)及患者健康问卷-9(PHQ-9)观察各组治疗效果及抑郁症状改善情况。结果经治疗后,各组HAMD-17量表评分较治疗前均有降低;除单纯草酸艾司西酞普兰治疗组外,其余两组PHQ9量表抑郁评分较治疗前均有降低。总体来说,草酸艾司西酞普兰联合rTMS治疗组评分均低于非联合治疗组,差异有统计学意义(P<0.05),但高频rTMS治疗组与低频rTMS治疗组之间差异不明显(P>0.05)。结论草酸艾司西酞普兰联合rTMS能够降低青壮年PSD患者HAMD-17评分及PHQ-9评分,改善抑郁症状。Objective To explore the repetitive transcranial magnetic stimulation(rTMS)combined with escitalopram oxalate in the treatment of post-stroke depression(PSD)in young and middle-aged patients.Methods A total of 106 young and middle-aged stroke patients with PSD admitted to the First Central Hospital of Baoding City and the Hebei Sixth People's Hospital from June 2021 to July 2023 were selected.They were randomly divided into Escitalopram oxalate treatment group(38 cases),Escitalopram oxalate combined with high frequency rTMS treatment group(32 cases)and Escitalopram oxalate combined with low frequency rTMS treatment group(36 cases).After 4 weeks of treatment,the therapeutic effect and depressive symptoms of each group were observed by Hamilton Depression Scale 17(HAMD-17)and Patient Health Questionnaire-9(PHQ-9).Results After treatment,HAMD-17 scale scores in all groups were lower than before treatment;except the escitalopram oxalate treatment group,the scores of PHQ-9 of the other two groups were lower than before treatment.In general,the scores of escitalopram oxalate combined with rTMS treatment group were lower than those of non-combined treatment group,with statistical significance(P<0.05),but there was no significant difference between high-frequency rTMS treatment group and low-frequency rTMS treatment group(P>0.05).Conclusion Escitalopram oxalate combined with rTMS can reduce HAMD-17 and PHQ-9 scores and improve depressive symptoms in young and middle-aged patients with PSD.

关 键 词：卒中后抑郁 经颅磁刺激 草酸艾司西酞普兰 青壮年 

分 类 号：R743.32[医药卫生—神经病学与精神病学]